Wesana Health Commits Funding of $1.5 Million To Support MAPS’ Research...

COMPASS Pathways acquires IP portfolio of novel psychedelic compounds and prodrugs

Perception Neuroscience initiates Phase 2a study of PCN-101 (R-ketamine) for treatment...

Mindset Pharma Further Validates Lead Candidate, MSP-1014, as a Next Generation...

NeonMind Announces Divestiture of Consumer Related and Other Non-Core Assets

PharmaTher Provides Product Pipeline Updates and Anticipated Milestones for Q4-2021 and...

The Therapeutic Effects of Psychedelics: 2A or Not 2A? – Part...

Psychedelic Bulletin: Proliferation of Psilocybin-Related Drug Development; Biden-Harris Administration Aims to...

PTSF76 – Spiritual Emergence and Healing

Hamilton Morris joins COMPASS Pathways to research new psychedelic compounds

Load more